Loading...
XSTOLPGO
Market cap1mUSD
Dec 23, Last price  
0.14SEK
1D
-1.16%
1Q
-49.56%
IPO
-98.58%
Name

Lipigon Pharmaceuticals AB

Chart & Performance

D1W1MN
XSTO:LPGO chart
P/E
—
P/S
1.05
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
38.62%
Rev. gr., 5y
290.80%
Revenues
16m
+4,106.92%
018,0001,743,0004,278,0003,180,000390,00016,407,000
Net income
-12m
L-67.80%
-3,030,438,000-3,768,000-5,038,000-8,312,000-41,118,000-37,668,000-12,128,000
CFO
-14m
L-61.78%
0-3,263,000-5,559,000-8,625,000-35,300,000-37,467,000-14,319,000

Profile

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.
URL
https://www.lipigon.se/
IPO date
Mar 01, 2021
Employees
7
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
16,407
4,106.92%
390
-87.74%
3,180
-25.67%
Cost of revenue
21,524
31,679
81,378
Unusual Expense (Income)
NOPBT
(5,117)
(31,289)
(78,198)
NOPBT Margin
Operating Taxes
(37)
5
Tax Rate
NOPAT
(5,117)
(31,252)
(78,203)
Net income
(12,128)
-67.80%
(37,668)
-8.39%
(41,118)
394.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
43,265
22,600
56,312
BB yield
-156.55%
-160.80%
-70.60%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
3,487
Net debt
(31,927)
(9,637)
(28,467)
Cash flow
Cash from operating activities
(14,319)
(37,467)
(35,300)
CAPEX
(119)
Cash from investing activities
(119)
Cash from financing activities
36,701
18,614
51,092
FCF
(5,094)
(31,228)
(77,867)
Balance
Cash
31,927
9,637
28,467
Long term investments
Excess cash
31,107
9,618
28,308
Stockholders' equity
(99,109)
(98,946)
(62,425)
Invested Capital
127,553
102,817
85,387
ROIC
ROCE
EV
Common stock shares outstanding
64,121
17,791
12,271
Price
0.43
-45.44%
0.79
-87.85%
6.50
 
Market cap
27,636
96.63%
14,055
-82.38%
79,762
 
EV
(4,291)
4,418
51,295
EBITDA
(5,093)
(31,265)
(78,175)
EV/EBITDA
0.84
Interest
3
37
5
Interest/NOPBT